Pentosan Polysulfate Maculopathy-Prescribers Should Be Aware

Imran H Yusuf^{1

2}, Peter Charbel Issa^{1

2}, Andrew J Lotery³

Affiliations

¹ Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom.
² Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
³ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Comment

Imran H Yusuf et al. JAMA Ophthalmol. 2020.

. 2020 Aug 1;138(8):900-902.

doi: 10.1001/jamaophthalmol.2020.2364.

Imran H Yusuf^{1

2}, Peter Charbel Issa^{1

2}, Andrew J Lotery³

¹ Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom.
² Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
³ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

No abstract available

Comment on

Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.
Shah R, Simonett JM, Lyons RJ, Rao RC, Pennesi ME, Jain N. Shah R, et al. JAMA Ophthalmol. 2020 Aug 1;138(8):894-900. doi: 10.1001/jamaophthalmol.2020.2349. JAMA Ophthalmol. 2020. PMID: 32644147 Free PMC article.